Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(03): 139-142
DOI: 10.4103/0971-5851.92810
ORIGINAL ARTICLE

Hyponatremia of non-small cell lung cancer: Indian experience

Chinmoy K Bose
Department of Clinical Research, Netaji Subhash Chandra Bose Cancer Research Institute, Park Street, Kolkata, West Bengal, India
,
Subhashis Dey
Department of Clinical Research, Netaji Subhash Chandra Bose Cancer Research Institute, Park Street, Kolkata, West Bengal, India
,
Ashis Mukhopadhyay
Department of Clinical Research, Netaji Subhash Chandra Bose Cancer Research Institute, Park Street, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Hyponatremia is a hazardous complication of lung cancer and its treatment. It is seen at presentation in approximately 15% of patients with small-cell lung cancer (SCLC) and 1% of patients with non-small cell lung cancer (NSCLC). Platinum compounds used as first-line agents along with taxols frequently cause hyponatremia. Till date there is no data on its prevalence in patients with advanced lung cancer in the Indian subcontinent. Aim: This study was undertaken to find out its incidence before and after institution of chemotherapy and to observe the results of treatment of hyponatremia in a group of lung cancer patient. Materials and Methods: Forty patients with advanced lung cancer (25 patients with stage III disease and 15 with stage IV disease) were included in the study. Variables looked at included, but were not limited to, serum sodium, serum albumin, serum alkaline phosphatase, serum lactate dehydrogenase, and hemoglobin. These variables were measured as per the standard clinical laboratory procedure. No ethics approval was required as these parameters are routinely measured in such patients. Results: In the chemo-naïve state, one out of five cases with SCLC (20%) had hyponatremia at presentation; among the 35 cases of NSCLC, 7 patients (20%) had hyponatremia at presentation, which is in sharp contrast to earlier reports of 1% prevalence of hyponatremia in this group. Among the 27 cases who died within 6 months, 11 had hyponatremia; this finding was statistically highly significant. Conclusion: In India, NSCLC patients are at high risk of having hyponatremia at presentation and this is significantly associated with a worse outcome.

Keywords

Hyponatremia - non-small cell lung cancer - syndrome of inappropriate secretion of antidiuretic hormone


Publication History

Article published online:
06 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Asadollahi K, Beeching N, Gill G. Hyponatremia as a risk factor for hospital mortality. QJM 2006;99:877-80.
  • 2 Behera D, Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci 2004;46:269-81.
  • 3 Johnson BE, Chute JP, Rushin J, Williams J, Le PT, Venzon D, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J RespirCrit Care Med 1997;156:1669-78.
  • 4 Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
  • 5 Common Terminology Criteria for Adverse Events (CTCAE) v4.0 available from: https://cabig.nci.nih.gov/workspaces/VCDE/workspaces/VCDE/CTCAE [Last accessed on 2010 Dec 05].
  • 6 Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529-42.
  • 7 Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006;12:888-96.
  • 8 Sorensen JB, Anderson MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97-110.
  • 9 Tisi E, Cassina E, Ballabio D, Benenti C, Perego M, Barni S, et al. Blood levels of atrial natriuretic peptide in non-small cell lung cancer and their changes with surgery. Int J Biol Markers 1992;7:121-2.
  • 10 Tho LM, Ferry DR. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety? Postgrad Med J 2005;81:e17.
  • 11 Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daure JP, et al. Quality of life and comorbidity score as prognostic determinants in non-small cell lung cancer patients. Ann Oncol 2008;19:1458-64.